Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Nucala loss of exclusivity?

See the DrugPatentWatch profile for Nucala

“Nucala” (mepolizumab) is approaching/has entered loss of exclusivity (LoE) in some countries/markets, but the exact timing depends on the country, formulation, and local patent/regulatory history.

What “loss of exclusivity” means (in practice)

  • After exclusivity ends, generic and/or biosimilar manufacturers may be able to market competing versions (subject to approval pathways and regulatory requirements).
  • This usually leads to price competition, formulary changes, and potentially broader access.

What to check to get the exact LoE date

If you tell me which country/market you mean (e.g., US, EU5, UK, Canada, Australia, Japan), I can narrow it down. Otherwise, the key inputs are:

  • Regulatory region (FDA/EMA/etc.)
  • Indication(s) (e.g., severe eosinophilic asthma, EGPA, HES/NP, etc.)
  • Formulation/route (Nucala is subcutaneous by prefilled syringe/auto-injector or IV in some places depending on local labeling)
  • Specific exclusivity type:
    • patent expiry (most common driver)
    • supplementary protection certificates (SPCs) / extension mechanisms
    • biologics exclusivity / data exclusivity (where applicable)

Quick question

Which country or region do you want the LoE for—US, EU (which countries), UK, Canada, or another?
And are you focused on all indications or a specific one?



Other Questions About Nucala :

Nucala? When does nucala patent expire? How does nucala differ from xolair? How does nucala treat asthma? Nucala patent expiration? Nucala biosimilar? Nucala patent expiration date?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The AI claims are about regulatory exclusivity, patents, and biosimilar launch barriers, which are not supported or addressed by the provided NUCALA (mepolizumab) FDA label excerpts (Sections 1, 2, 4, 5, 6, 7, 8, 12, 14). No label-based indication/dosing/safety/interaction claims were evaluated against the provided label text.

Category Scores

Indication
0
Poor
Indication
0
Poor

Accurate Statements

Unsupported Statements

Nucala (mepolizumab) is a biologic.
Not supported by the provided label excerpts.
For biologics, data exclusivity and other regulatory exclusivities can expire even if patents are still in force.
Not addressed in the provided label excerpts.
Patent expiry (or successful patent challenges) can delay biosimilar launches.
Not addressed in the provided label excerpts.
A biosimilar may be approved based on regulatory requirements but still be blocked from launch until patent barriers clear.
Not addressed in the provided label excerpts.
Even if exclusivity ends, patents covering the product, its formulation, or specific indications can still block commercial launch of biosimilars.
Not addressed in the provided label excerpts.
In practice, biosimilar entry depends on whether approvals are granted.
Not addressed in the provided label excerpts.
In practice, biosimilar entry depends on whether patents are expired or successfully challenged for the targeted market/indication.
Not addressed in the provided label excerpts.
In practice, biosimilar entry depends on whether courts grant a launch carve-out or the patent situation changes through settlement or litigation.
Not addressed in the provided label excerpts.
For mepolizumab, market barriers can come from patent families covering the biologic molecule.
Not addressed in the provided label excerpts.
For mepolizumab, market barriers can come from process/formulation patents.
Not addressed in the provided label excerpts.
For mepolizumab, market barriers can come from method-of-use or indication-related patents.
Not addressed in the provided label excerpts.
For mepolizumab, market barriers can come from regulatory exclusivity periods tied to the first approval and subsequent protected indications.
Not addressed in the provided label excerpts.
In the US, the loss of exclusivity concept typically hinges on US Biologics Price Competition and Innovation Act (BPCIA) timelines and the specific patents listed for mepolizumab.
Not addressed in the provided label excerpts.

Contradictions

Important Omissions

Any FDA-label-anchored information relevant to the provided claims (regulatory exclusivity/patent/biosimilar launch barriers) is absent from the supplied NUCALA label excerpts; no on-label statements can be verified.
Importance: High

Safety Assessment

Potential Patient Risk: Low
The claims are regulatory/market-access assertions and do not directly contradict NUCALA’s labeled clinical safety, dosing, contraindications, warnings, or administration in the provided excerpts. However, they are not label-supported.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
All claims concern regulatory exclusivity/patent/biosimilar launch barriers and are not supported by the provided FDA label excerpts for NUCALA.

Suggested Improvement
Limit evaluation to label-supported content (Sections 1, 2, 4, 5, 6, 7, 8, 12, 14). Provide label excerpts that specifically address biologic status or any regulatory exclusivity/patent-related information if available; otherwise, omit these non-label regulatory assertions.

Drug Brand Mention Assessment

Branding Score
47
Visibility
55
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Nucala’s (mepolizumab) loss of exclusivity

Core Claims
  • Nucala (mepolizumab) is a biologic.
  • Loss of exclusivity usually refers to the end of regulatory marketing protections and/or when key patents stop blocking generic or biosimilar competition.
  • The timing can differ by country and by the specific protection being counted.
  • Even if exclusivity ends, patents can still block commercial launch.
  • For mepolizumab, barriers can come from patent families, process/formulation patents, method-of-use/indication patents, and regulatory exclusivity periods.
Differentiators
  • Loss of exclusivity for a biologic like Nucala happens as a sequence of events.
  • Biosimilar entry depends on approvals, patent expiry/challenges, and potential launch carve-outs or changes through settlement/litigation.
  • The timeline depends on the jurisdiction’s rules and the relevant patent set.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 54%
60 #2 Yes